Key Highlights
- 5.1% was the mean weight regain for Fractyl Health (NASDAQ:GUTS) Revita patients at six months versus 8.2% for sham in the REMAIN-1 pivotal cohort, a co-primary endpoint win with a p-value of 0.0023, per the company release dated October 16, 2026.
- 48% is the decline per published market data (October 16, 2026 premarket): USD 2.17 against the October 15 close of USD 4.16, own arithmetic. Relative volume was 43.45, and the 8-K filed with the trial data discloses no financing.
- USD 47.1 million of cash at June 30, 2026 sits beside management's substantial doubt regarding going concern, per the 10-Q. Fractyl Health (NASDAQ:GUTS) guides to a De Novo submission in late fourth quarter 2026 and 12-month data in the first quarter of 2027.
- 1-for-12 is the reverse split effective October 2, 2026, with split-adjusted trading from October 5. Per published market data, Fractyl Health (NASDAQ:GUTS) carries a market capitalization of USD 55.18 million and a Strong buy analyst consensus.
Price Action and Catalyst Review
On October 16, 2026, Fractyl Health (NASDAQ:GUTS) reported six-month data from REMAIN-1, a randomized, double-blind, sham-controlled study of 308 adults who first lost at least 15% of body weight on tirzepatide. Revita patients retained 80% of that loss versus 67% for sham, per the company release. Published market data show 8.52 million shares traded against an implied average of 196,000 (own arithmetic). Turnover was USD 18.5 million (price times volume, own arithmetic), or 33.5% of market capitalization.
Efficacy Gap and Endpoint Scope
Neither the release nor the 8-K states a cause for the decline, so any explanation is interpretation. The gap between 8.2% and 5.1% is 3.1 percentage points (own arithmetic). The 3.8% regain for ablations of 20 centimeters or more is a post hoc subgroup. The second co-primary endpoint, weight loss of at least 5% held at 12 months against a 50% performance goal, reads out in the first quarter of 2027. A shareholder class action has a lead plaintiff deadline of October 20, 2026.
Capital Structure, Runway and Dilution
Cash fell 42% to USD 47.1 million between December 31 and June 30, 2026, per the 10-Q, with USD 38.4 million used in operations over six months. That is USD 6.4 million per month, a runway of 7.4 months from June 30, or mid-February 2027 (own arithmetic, excluding new financing). The at-the-market sales program ended in March 2026, and a Nasdaq minimum bid notice dated March 13, 2026 preceded the reverse split. No raise is announced, yet funding the filing and launch requires new capital, and each share or warrant sold dilutes holders.
Where Things Stand
Fractyl Health (NASDAQ:GUTS) fell 48% because investors weighed a narrow 3.1 percentage point efficacy gap and a short cash runway against a study that met its endpoint, though the company has not explained the move and no financing was identified through October 16, 2026. The co-primary regain endpoint was met, so this is not a failed study. Open questions are whether the 12-month hurdle is cleared in the first quarter of 2027, whether the FDA accepts the De Novo filing planned for late 2026, and how operations are funded beyond mid-February 2027.






Please wait processing your request...